Abstract:Long-acting and implantable drug delivery systems (IDDSs) encompass a variety of therapeutic implements placed inside the body to exert a certain therapeutic action for an extended duration. They are classified under different categories from pharmaceutical science and regulatory perspectives. If the system is solely classified as a drug, a device, or a biologic, then the regulatory pathway is rather straightforward. However, if the system consists of two or more regulated components (drugs, medical devices, or biological products) combined prior to use, the systems are recognized as combination products. Regulatory approval for combination products is more complicated and less formalized than for the approval of each component independently. The rapid growth in combination products available in the global pharmaceutical and biotechnology marketplace has prompted both the United States Food and Drug Administration (US FDA) and the European Union (EU) to update their guidance on how such products are reviewed and approved for sale. The new EU draft guidance, Guideline on the Quality Requirements for Drug-Device Combinations, and US draft guidance, Principles of Premarket Pathways for Combination Products, are the latest attempts by each regulatory body to adequately regulate combination products. The progression of long-acting and IDDSs covers a variety of therapeutic devices placed inside the body to exert a certain therapeutic action for an extended duration. They are classified under different categories from pharmaceutical science and regulatory perspectives. The uniqueness and variety of IDDSs prevent the application of a standardized regulation for all of these products; therefore sponsors face regulatory challenges to register and market their products. This review investigates the requirements imposed by the US FDA and the European Medicines Agency (EMA) regarding regulatory challenges and guidance on how many IDDSs are classified, regulated, and introduced in the market. Businesses that want to register and maintain (IDDSs) products in the United States and the EU face two markets that are quite different from each other. These markets are not comparable to each other; their regulations are different from and independent of each other. Complete knowledge of the regulations in all their interpretation and nuances is necessary for businesses that want to market IDDS products into the United States or the EU. The regulatory classification of any IDDS, as a “drug,” “medical device,” or a “combination product,” is the foundation in determining the regulatory pathway, which ultimately determines the regulatory and quality standard requirements preceding the marketing approval. IDDSs are generally recognized as combination products as they consist of two or more regulated components (drugs, medical devices, or biological products) combined prior to use to function as a single entity.

Pre-ANDA strategy and Human Factors activities to de-risk pharmaceutical companies ANDA submission of drug–device combination products: case study of a formative Comparative Use Human Factors study

A Comparative Analysis of Generic Drug Assessment and Regulatory Approval in the USA, Europe and India

Project risk evaluation with design of experiment: A case of developing a generic drug analytic method development project

A Risk-Based Assessment for Determining the Pharmacokinetic Comparability Requirements of Biologic-Device Combination Products Administered by Subcutaneous Injection

Factors That Facilitate Regulatory Approval for Drug-Device Combination Products in the European Union and United States of America: A Mixed Method Study of Industry Views

Evaluating the Safety Profile of Non-Active Implantable Medical Devices Compared with Medicines

AIDE: Adaptive intrapatient dose escalation designs to accelerate Phase I clinical trials

Novel Design and Analysis for Rare Disease Drug Development

Regulatory strategies for early device development and approval

Scientific Considerations for Stability Studies of Drug Substances Supporting Abbreviated New Drug Applications (ANDAs)

Challenges for clinical translation of long-acting and implantable drug delivery systems

Toward standardized premarket evaluation of computer aided diagnosis/detection products: insights from FDA-approved products

Preclinical and Clinical Studies Supporting Development of Drug + Digital Combination Therapies for Chronic Diseases

Considerations for Human ADME Strategy and Design Paradigm Shift(s) - An Industry White Paper

Integrative Analysis of Randomized Clinical Trial and Observational Study Data to Inform Post-marketing Safety Decision-Making

New Visualization Models of Designation Pathway and Group Categorization of Device–Drug and Device–Biologic Combination Products Classification in the United States: Analysis of FDA Capsular Decisions

Harmonizing Safety and Speed: A Human-Algorithm Approach to Enhance the FDA's Medical Device Clearance Policy

Digital Tools-Regulatory Considerations for Application in Clinical Trials

An industry perspective on the FDA modernization act 2.0/3.0: Potential next steps for sponsors to reduce animal use in drug development

An accelerated access pathway for innovative high-risk medical devices under the new European Union Medical Devices and health technology assessment regulations? Analysis and recommendations

Considerations for Industry—Preparing for the FDA Model‐Informed Drug Development (MIDD) Paired Meeting Program